Loading...
OTCM
IMUC
Market cap21mUSD
Oct 08, Last price  
0.10USD
1D
-43.60%
1Q
-64.80%
Jan 2017
-99.54%
IPO
-99.98%
Name

Eom Pharmaceutical Holdings Inc

Chart & performance

D1W1MN
OTCM:IMUC chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
22.92%
Rev. gr., 5y
%
Revenues
0
00000300,00000000000000000
Net income
-2m
L+1.61%
0-246,004-5,152,713-3,614,753-3,059,730-2,626,205-6,150,142-5,719,903-14,495,139-8,750,161-9,392,560-12,924,719-23,397,538-18,516,568-1,452,992-2,679,170-2,646,904-1,612,737-1,892,133-1,922,557
CFO
-1m
L-44.25%
0-54,709-527,719-912,003-1,945,447-2,151,781-4,253,560-6,383,742-12,380,013-8,787,217-9,936,802-19,039,401-19,864,442-16,671,777-1,237,021-2,306,385-2,623,322-1,421,984-2,679,595-1,493,907

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. It also develops EOM 147, an investigational broad-spectrum aminosterol with an intracellular mechanism that has completed Phase 2 clinical trial for the treatment of age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vain occlusion. EOM Pharmaceuticals Holdings, Inc. was founded in 2020 and is headquartered in Montvale, New Jersey.

Key people

Irach Taraporewala
President, Chief Executive Officer, Director · since 2021
Shalom Hirschman
Chief Scientific Officer · since 2021
Wayne Danson
Chief Financial Officer, Treasurer · since 2021
Eli Goldberger
Chairman of the Board, Chief Operating Officer · since 2021
Frank Douglas
Independent Director · since 2022
Julie Kampf
Independent Director · since 2022
Robert Lehman
Independent Director · since 2022
URL
https://imuc.com/
IPO date
Sep 19, 2006
Employees
3
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
23622 Calabasas Road
Suite 300
Calabasas, CA 91302
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT